Skip to main content

Raymond T. Bartus, PhD

President at RTBioconsultants, Inc

Location: San Diego, CA United States

Raymond T. Bartus received a PhD in the neurosciences at North Carolina State University and has since focused his career on translational R&D in industry, while also maintaining strong academic and scientific ties. He has participated in the research and development of more than a dozen treatments that progressed into human clinical trials, nearly half of which have received FDA marketing approval. He has also published ~250 scientific papers and is listed by the Institute of Scientific Information as a “Highly Cited Researcher,” placing him in the top 0.5 percent of all scientists. He was the inaugural editor-in-chief for Neurobiology of Aging (for a decade) and has served on numerous elite panels, including for the FDA, U.S. Congress, NIH and Secretary of HHS.

Dr. Bartus’ translational research and development experience extends 30+ years, gained during tenures at major multi-national pharmaceutical companies as well as smaller development-stage biotech companies. He serves as president of RTBioconsultants, Inc. From 2002 to 2013, he worked at Ceregene, where he had overall responsibility for non-clinical, clinical and regulatory activities involving their neurotrophic/gene therapy products for neurodegenerative diseases like Parkinson’s (AAV2-neurturin or CERE-120) and Alzheimer’s (AAV2-NGF or CERE-110). During his ten-year tenure at Alkermes, Dr. Bartus conceived, championed and led the pre-clinical development and initial clinical strategy for Vivitrol®, a once-a-month injectable treatment for alcoholism that received FDA approval in 2006. He is also recognized as one of the originators of the ‘Cholinergic Hypothesis,’ which led directly to the first four drugs approved by the FDA for Alzheimer’s disease.

Associated Grants

  • CERE-120 Long-Term Subject Follow-Up


  • A Phase II Clinical Trial of Neurturin (NTN) Gene Therapy for PD


  • Phase I Study of CERE-120 [Adeno-Associated Virus (AAV)-Neuturin (NTN)] to Assess the Safety and Tolerability of Intraputaminal Delivery


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.